#bpc-157
6 pieces tagged bpc-157.
- Where the line isWhere research peptides sit on the WADA Prohibited ListFDA status and WADA status are different questions with different answers. Where BPC-157, TB-500, the GHRPs, the GHRH analogues, ipamorelin and Melanotan II sit on the 2026 Prohibited List, and what strict liability means.
- Reading the paperworkMass spectrometry identity: what a one-dalton match provesESI and MALDI in plain terms, why a peptide shows up at several m/z values at once, monoisotopic against average mass, and a worked example on a stocked fifteen-residue peptide from its PubChem entry.
- Where the line isApproved, investigational, or neither: a status table for 27 peptidesOne table, three statuses. Which peptides have an FDA-approved product, which are in a sponsor's trial program, and which have neither, with the compounding category and WADA line for each, as of September 21, 2026.
- Where the line isCategory 1, Category 2 and the 503A bulks list in 2026Twelve peptides left FDA's Category 2 in April, GHK-Cu went back into Category 1 in May, and an advisory committee voted in July. None of it put a peptide on the 503A bulks list. A dated tracker.
- Where the line isBPC-157 in 2026: not banned, not approved, not compoundableThree separate questions get asked as one. BPC-157 is not a controlled substance, is not an FDA-approved drug, and has no lawful 503A compounding pathway. What the molecule is and where each answer comes from, dated.
- Where the line isCompounding pharmacy, outsourcing facility or research supplierA 503A pharmacy, a 503B outsourcing facility and a research supplier operate under three different sets of rules. What each one is, why a pharmacy cannot compound BPC-157 today, and why a research vial has no place in the other two chains.
Nothing here is medical advice. Everything on this site is supplied for laboratory research use only.